MK 0343Subtype-selective GABAA receptor partial agonist CAS# 233275-76-8 |
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- Proflavine Hemisulfate
Catalog No.:BCC4707
CAS No.:1811-28-5
- Lenalidomide (CC-5013)
Catalog No.:BCC2245
CAS No.:191732-72-6
- Carboxypeptidase G2 (CPG2) Inhibitor
Catalog No.:BCC1452
CAS No.:192203-60-4
- NSC 146109 hydrochloride
Catalog No.:BCC2410
CAS No.:59474-01-0
- Oxaliplatin
Catalog No.:BCC3932
CAS No.:61825-94-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 233275-76-8 | SDF | Download SDF |
PubChem ID | 22609888 | Appearance | Powder |
Formula | C19H17F2N7O | M.Wt | 397.38 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 50 mM in ethanol | ||
Chemical Name | 7-cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine | ||
SMILES | CN1C(=NC=N1)COC2=NN3C(=NN=C3C4=C(C=CC=C4F)F)C=C2C5CCC5 | ||
Standard InChIKey | GOIFCXRIFSYPFG-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H17F2N7O/c1-27-16(22-10-23-27)9-29-19-12(11-4-2-5-11)8-15-24-25-18(28(15)26-19)17-13(20)6-3-7-14(17)21/h3,6-8,10-11H,2,4-5,9H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Subtype-selective GABAA partial agonist (Ki values are 0.21, 0.22, 0.23 and 0.40 for α3, α1, α5 and α2 respectively); occupies the benzodiazepine site of GABAA receptors. Displays greater agonist efficacy at α3 compared to α1. Exhibits anxiolytic and non-sedating properties in rodent models. Brain penetrant. |
MK 0343 Dilution Calculator
MK 0343 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5165 mL | 12.5824 mL | 25.1648 mL | 50.3297 mL | 62.9121 mL |
5 mM | 0.5033 mL | 2.5165 mL | 5.033 mL | 10.0659 mL | 12.5824 mL |
10 mM | 0.2516 mL | 1.2582 mL | 2.5165 mL | 5.033 mL | 6.2912 mL |
50 mM | 0.0503 mL | 0.2516 mL | 0.5033 mL | 1.0066 mL | 1.2582 mL |
100 mM | 0.0252 mL | 0.1258 mL | 0.2516 mL | 0.5033 mL | 0.6291 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Nefopam HCl
Catalog No.:BCC4681
CAS No.:23327-57-3
- Cephalexin monohydrate
Catalog No.:BCC4096
CAS No.:23325-78-2
- Emodin-8-beta-D-glucoside
Catalog No.:BCN6329
CAS No.:23313-21-5
- Delta 7-avenasterol
Catalog No.:BCN3212
CAS No.:23290-26-8
- Probucol
Catalog No.:BCC4833
CAS No.:23288-49-5
- m-NH2-Tyr-OH.2HCl
Catalog No.:BCC3340
CAS No.:23279-22-3
- VAL-083
Catalog No.:BCC2024
CAS No.:23261-20-3
- Bay 36-7620
Catalog No.:BCC5915
CAS No.:232605-26-4
- 4'-O-Methylvitexin
Catalog No.:BCN2642
CAS No.:2326-34-3
- Guanabenz Acetate
Catalog No.:BCC4327
CAS No.:23256-50-0
- Dimaprit dihydrochloride
Catalog No.:BCC6672
CAS No.:23256-33-9
- Riddelline
Catalog No.:BCN2133
CAS No.:23246-96-0
- Glycoborinine
Catalog No.:BCN7462
CAS No.:233279-39-5
- L-Ser(Bzl)-ol
Catalog No.:BCC2579
CAS No.:23356-96-9
- Vinleurosine
Catalog No.:BCN2608
CAS No.:23360-92-1
- (1S,2R)-2-Amino-1,2-diphenylethanol
Catalog No.:BCC8385
CAS No.:23364-44-5
- Theviridoside
Catalog No.:BCN5084
CAS No.:23407-76-3
- Phalaenopsine T
Catalog No.:BCN2014
CAS No.:23412-97-7
- Phalaenopsine La
Catalog No.:BCN2015
CAS No.:23412-99-9
- 7-Isopentenyloxy-gamma-fagarine
Catalog No.:BCN5085
CAS No.:23417-92-7
- Tetrahydropiperin
Catalog No.:BCN6708
CAS No.:23434-88-0
- Swertianolin
Catalog No.:BCN2759
CAS No.:23445-00-3
- Irisolidone
Catalog No.:BCN8496
CAS No.:2345-17-7
- Physcion 1-glucoside
Catalog No.:BCN8170
CAS No.:23451-01-6
MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans.[Pubmed:20147571]
J Psychopharmacol. 2011 Mar;25(3):314-28.
MRK-409 binds to alpha1-, alpha2-, alpha3- and alpha5-containing human recombinant GABA(A) receptors with comparable high affinity (0.21-0.40 nM). However, MRK-409 has greater agonist efficacy at the alpha3 compared with alpha1 subtypes (respective efficacies relative to the full agonist chlordiazepoxide of 0.45 and 0.18). This compound readily penetrates the brain in rats and occupies the benzodiazepine site of GABA(A) receptors, measured using an in vivo [(3)H]flumazenil binding assay, with an Occ(50) of 2.2 mg/kg p.o. and a corresponding plasma EC(50) of 115 ng/mL. Behaviourally, the alpha3-preferring agonist efficacy profile of MRK-409 produced anxiolytic-like activity in rodent and primate unconditioned and conditioned models of anxiety with minimum effective doses corresponding to occupancies, depending on the particular model, ranging from approximately 35% to 65% yet there were minimal overt signs of sedation at occupancies greater than 90%. In humans, however, safety and tolerability studies showed that there was pronounced sedation at a dose of 2 mg, resulting in a maximal tolerated dose of 1 mg. This 2 mg dose corresponded to a C(max) plasma concentration of 28 ng/mL, which, based on the rodent plasma EC(50) for occupancy of 115 ng/mL, suggested that sedation in humans occurs at low levels of occupancy. This was confirmed in human positron emission tomography studies, in which [(11)C]flumazenil uptake following a single dose of 1 mg MRK-409 was comparable to that of placebo, indicating that occupancy of GABA(A) receptor benzodiazepine binding sites by MRK-409 was below the limits of detection (i.e. <10%). Taken together, these data show that MRK-409 causes sedation in humans at a dose (2 mg) corresponding to levels of occupancy considerably less than those predicted from rodent models to be required for anxiolytic efficacy ( approximately 35-65%). Thus, the preclinical non-sedating anxiolytic profile of MRK-409 did not translate into humans and further development of this compound was halted.
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.[Pubmed:18187530]
J Psychopharmacol. 2008 Jan;22(1):24-32.
The use of non-selective gamma-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered by unfavourable side effects. some of these may be associated with binding properties to certain subtypes of the GABA(A) receptor that are unnecessary for therapeutic effects. MK-0343 was designed to be a less sedating anxiolytic, based on reduced efficacy at the alpha1 subtype and significant efficacy at alpha2 and alpha3 subtypes of the GABA(A) receptor. This paper is a double-blind, four-way cross-over (n = 12) study to investigate the effects of MK-0343 (0.25 and 0.75 mg) in comparison to placebo and an anxiolytic dose (2 mg) of the non-selective agonist lorazepam. Effects were measured by eye movements, body sway, Visual Analogue scales (VAS) and memory tests. Lorazepam impaired saccadic peak velocity (SPV), VAs alertness scores, postural stability and memory and increased saccadic latency and inaccuracy. MK-0343 0.75 mg was equipotent with lorazepam as indicated by SPV (-42.4 deg/s), saccadic latency (0.02 s) and VAS alertness scores (1.50 ln mm), while effects on memory and postural stability were smaller. MK-0343 0.25 mg only affected postural stability to a similar extent as MK-0343 0.75 mg. The effect profile of MK-0343 0.75 mg is different from the full agonist lorazepam, which could reflect the selective actions of this compound. Although less effect on VAS alertness was expected, diminished effects on memory and postural stability were present. Clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile.